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Abstract: In the field of antivenom research, development, and manufacture, it is often advised to
follow the World Health Organization’s (WHO) guidelines for the production, control, and regulation
of snake antivenom immunoglobulins, which recommend the use of preincubation assays to assess
the efficacy of snakebite therapeutics. In these assays, venom and antivenom are mixed and incubated
prior to in vivo administration to rodents, which allows for a standardizable comparison of antivenoms
with similar characteristics. However, these assays are not necessarily sufficient for therapeutics with
significantly different pharmacological properties than antibody-based antivenoms, such as small
molecule inhibitors, nanoparticles, and other modalities. To ensure that the in vivo therapeutic utility
of completely novel toxin-neutralizing molecules with no history of use in envenoming therapy and
variable pharmacokinetics is properly evaluated, such molecules must also be tested in preclinical
rescue assays, where rodents are first challenged with appropriate doses of venoms or toxins, followed
by the administration of neutralizing modalities after an appropriate time delay to better mimic
the real-life scenarios faced by human snakebite victims. Such an approach takes the venom (or
toxin) toxicokinetics, the drug pharmacokinetics, and the drug pharmacodynamics into consideration.
If new modalities are only assessed in preincubation assays and not subjected to evaluation in rescue
assays, the publication of neutralization data may unintentionally misrepresent the actual therapeutic
efficacy and suitability of the modality being tested, and thus potentially misguide strategic decision
making in the research and development of novel therapies for snakebite envenoming.
Keywords: Snakebite envenoming; rescue assays; preincubation assays; pre-clinical evaluation;
toxicokinetics; pharmacokinetics; envenoming therapy
Key Contribution: This paper highlights the importance of assessing the therapeutic potential of new
drugs for snakebite envenoming in assays that factor in toxicokinetics and drug pharmacodynamics.
Snakebite envenoming has gained renewed attention after it was recently reinstated on the World
Health Organization’s (WHO’s) List of Neglected Tropical Diseases [1], and the development of
novel therapeutics for envenoming has fortunately been stated as an important strategic goal for
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reducing the global burden of this debilitating affliction [2]. Researchers worldwide may now therefore
be increasingly incentivized to pursue the exploration of novel concepts and molecules for their
therapeutic utility in treating snakebite envenoming. While it is encouraging that scientific efforts
are strengthening novel research on therapeutics for envenoming and that a range of fundamentally
different strategies are being investigated [3,4], the proper preclinical evaluation of these novel therapies
must be carefully considered.
The reported efficacy of new therapeutics must be accompanied by a careful examination of
the assumptions underlying the assays used for evaluation. As a first step in the assessment of the
preclinical efficacy of a drug for snakebite envenoming, preincubation assays must be performed
(Figure 1) according to WHO guidelines [5]. These are excellent for gauging the feasibility of a drug
or molecule being effective in vivo, and candidate venom inhibitors that fail in preincubation assays
are likely not worth testing further [6,7]. From a pharmacological point of view, preincubation assays
are also the most reproducible way of determining the median effective dose (ED50) of a venom
inhibitory drug. However, this is clearly not enough for a thorough preclinical evaluation, because the
pharmacokinetic and pharmacodynamic profiles of these inhibitors, vis-à-vis the toxicokinetic profile
of venoms or toxins, should also be taken into consideration. The corollary is that it is especially
important for novel treatment modalities that have shown promising results in vitro to be tested
in vivo, not only in preincubation assays but also in rescue assays, i.e., those in which venom is injected
first and the inhibitory drug is administered after a time-lapse (see Figure 1). Indeed, an argument
could be made that existing, conventional, immunoglobulin-based antivenoms would also benefit
from re-evaluation in such assays given the complexities associated with the determination of what
extent the varying preclinical efficacies reported in preincubation assays reflect efficacy in the more
realistic scenario of rescue assays [8].
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Figure 1. Schematic representation of preincubation and rescue assays. In preincubation assays, 
venom(s) or toxin(s) are mixed with antitoxins or inhibitors, and they are preincubated prior to 
administration in a rodent. In rescue assays, the rodent is first injected with venom(s) or toxins. After 
a range of delayed time points, antitoxins or inhibitors are then administered via a route appropriate 
for the drug being tested. 
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Figure 1. Schematic representation of preincubation and rescue assays. In preincubation assays,
venom(s) or toxin(s) are mixed with antitoxins or inhibitors, and they are preincubated prior to
administration in a rodent. In rescue assays, the rodent is first injected with venom(s) or toxins. After a
range of delayed time points, antitoxins or inhibitors are then administered via a route appropriate for
the drug being tested.
Rescue assays more accurately reflect real-life envenoming and elucidate the influence of venom (or
toxin) toxicokinetics, drug pharmacodynamics, and drug pharmacokinetics. For example, if a drug is
rapidly eliminated from circulation, it will be unable to bind and inhibit venom toxins, hence requiring
a modification of the drug to extend its half-life. This would be evident in a rescue experiment, but it
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would not be evident in a preincubation assay. Moreover, new therapeutics for snakebite envenoming
may include drugs that do not directly bind and inhibit venom toxins; instead, they could modify
endogenous physiological processes, cellular receptors, and/or intracellular signaling molecules in the
body, thus combating the toxicity of venom through different mechanisms. For these types of drug,
the preincubation assay is not useful, whereas rescue experiments provide a more realistic scenario for
assessing their therapeutic potential. Furthermore, rescue experiments allow for venom and drugs to
be administered to an animal by different routes, e.g., venom by a subcutaneous route and a drug by the
intravenous, subcutaneous, or oral routes, depending on its properties (see, for example, [9]). This will
likely better reproduce the circumstances of a snakebite and the ensuing therapeutic intervention,
though further research is undoubtedly required to more accurately model the toxicokinetic properties
of murine envenoming to mimic those of a human snakebite. Ultimately, both preincubation assays
and rescue assays are valuable models of envenoming, and they should be viewed as complementary,
with new treatment modalities being evaluated with both types of assay and the need to follow
the principle of the 3Rs (replacement, reduction, and refinement) in animal experimentation always
kept in mind [10]. When interpreting the results of such assays, it should always be considered that
animal models do not necessarily reflect the dynamics of envenoming in humans. In the long term,
the preclinical evaluation of novel therapeutics should be followed by appropriate clinical testing.
As the battle against snakebite envenoming gains momentum and becomes further integrated into
the global health agenda, it is more important than ever that decision-makers have the most accurate
information at their disposal concerning new therapeutic approaches for tackling envenoming. For this
reason, the experimental approaches used to evaluate the preclinical efficacy of new snakebite therapies
should be carefully considered, and a high level of transparency regarding the limitations of studies
assessing novel treatment modalities must be prioritized. In this way, the limited resources available
for the field can be dedicated to those therapeutic candidates that offer the greatest chance of delivering
effective, safe, and affordable treatments to save the lives and limbs of the world’s impoverished
snakebite victims.
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